February 5, 2018 / 1:26 PM / 8 months ago

BRIEF-Sorrento's And Yuhan's Joint Venture, Immuneoncia, Receives Approval

Feb 5 (Reuters) - Sorrento Therapeutics Inc:

* SORRENTO’S AND YUHAN’S JOINT VENTURE, IMMUNEONCIA, RECEIVES APPROVAL TO BEGIN CLINICAL TRIAL OF ANTI-PD-L1 MONOCLONAL ANTIBODY IN SOUTH KOREA

* SORRENTO - SOUTH KOREAN MINISTRY FOR FOOD AND DRUG SAFETY HAS APPROVED IMMUNEONCIA THERAPEUTICS’ IND FOR INITIATION OF CLINICAL TRIALS FOR STI-A1015 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below